115 related articles for article (PubMed ID: 263356)
21. The effect of nomifensine on thyroid-stimulating hormone (TSH) in normal and hyperprolactinemic subjects.
Giusti M; Mazzocchi G; Mignone D; Tarditi W; Contessini M; Bessarione D; Giordano G
Neuroendocrinology; 1983 Dec; 37(6):406-10. PubMed ID: 6657002
[TBL] [Abstract][Full Text] [Related]
22. Defective regulation of prolactin secretion after successful removal of prolactinomas.
Camanni F; Ghigo E; Ciccarelli E; Massara F; Campagnoli C; Molinatti G; Müller EE
J Clin Endocrinol Metab; 1983 Dec; 57(6):1270-6. PubMed ID: 6415087
[TBL] [Abstract][Full Text] [Related]
23. [Indirect dopamine agonists and direct dopamine antagonists in the diagnosis of hyperprolactinemia].
De Leo V; Massafra C; La Marca S; De Leo M; Venturi C; Urbani TM; Genazzani AR
Boll Soc Ital Biol Sper; 1982 Aug; 58(16):1025-31. PubMed ID: 7138672
[TBL] [Abstract][Full Text] [Related]
24. The effect of nomifensine on prolactin secretion in patients with suspected pituitary microadenoma.
Jeske W; Stopińska U
Endokrynol Pol; 1981; 32(1):17-24. PubMed ID: 7250073
[No Abstract] [Full Text] [Related]
25. Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects.
Serri O; Kuchel O; Buu NT; Somma M
J Clin Endocrinol Metab; 1983 Feb; 56(2):255-9. PubMed ID: 6822635
[TBL] [Abstract][Full Text] [Related]
26. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
[TBL] [Abstract][Full Text] [Related]
27. Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women.
Petraglia F; De Leo V; Sardelli S; Mazzullo G; Gioffrè WR; Genazzani AR; D'Antona N
Gynecol Obstet Invest; 1987; 23(2):103-9. PubMed ID: 3583091
[TBL] [Abstract][Full Text] [Related]
28. Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia.
Sekiya K; Karashima T; Ikuyama S; Muta K; Kato K; Ibayashi H
Endocrinol Jpn; 1985 Apr; 32(2):207-14. PubMed ID: 4042986
[TBL] [Abstract][Full Text] [Related]
29. Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects.
Camanni F; Genazzani AR; Massara F; La Rosa R; Cocchi D; Müller EE
Neuroendocrinology; 1980; 30(1):2-6. PubMed ID: 7354887
[TBL] [Abstract][Full Text] [Related]
30. [Various aspects of dopaminergic function in patients with prolactin-secreting hypophyseal adenoma].
De Leo V; Franchi F; Danero S; Ricci MG; La Marca S; Urbani TM; Pieroni ML; D'Antona N; Genazzani AR
Boll Soc Ital Biol Sper; 1983 Dec; 59(12):1883-9. PubMed ID: 6671047
[TBL] [Abstract][Full Text] [Related]
31. Functional characterization of hypothalamic hyperprolactinemia.
Ferrari C; Rampini P; Benco R; Caldara R; Scarduelli C; Crosignani PG
J Clin Endocrinol Metab; 1982 Nov; 55(5):897-901. PubMed ID: 6811605
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients.
De Marinis L; Mancini A; Minnielli S; Masala R; Anile C; Maira G; Barbarino A
Metabolism; 1985 Oct; 34(10):917-22. PubMed ID: 4046835
[TBL] [Abstract][Full Text] [Related]
33. In vivo supersensitivity of the anterior pituitary of old female rats to dopaminergic inhibition of prolactin secretion.
Cocchi D; Novelli A; Ganzetti I; Müller EE
Gerontology; 1984; 30(6):345-9. PubMed ID: 6519436
[TBL] [Abstract][Full Text] [Related]
34. Different rebound rise in plasma prolactin during the postdopamine infusion phase in puerperal women and patients with pathological hyperprolactinemia.
Genazzani AR; Cavagnini F; Picotti GB; Ghigo E; De Leo V; Galva MD; Maraschini C; Muller EE
J Clin Endocrinol Metab; 1983 Dec; 57(6):1159-63. PubMed ID: 6630411
[TBL] [Abstract][Full Text] [Related]
35. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
Melis GB; Gambacciani M; Paoletti AM; Beneventi F; Mais V; Baroldi P; Fioretti P
J Clin Endocrinol Metab; 1987 Sep; 65(3):541-5. PubMed ID: 3624413
[TBL] [Abstract][Full Text] [Related]
36. Prolactin response to perphenazine. A sensitive and specific test for pituitary tumor in hyperprolactinemic women.
Mattox JH; Fortunato SJ
J Reprod Med; 1986 Dec; 31(12):1098-101. PubMed ID: 3795197
[TBL] [Abstract][Full Text] [Related]
37. Prolactin gene expression and secretion during pregnancy and lactation in the rat: role of dopamine and vasoactive intestinal peptide.
Escalada J; Cacicedo L; Ortego J; Melian E; Sánchez-Franco F
Endocrinology; 1996 Feb; 137(2):631-7. PubMed ID: 8593812
[TBL] [Abstract][Full Text] [Related]
38. Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition.
Nicoletti I; Filipponi P; Fedeli L; Gregorini G; Ambrosi F; Sfrappini M; Santeusanio F; Brunetti P
Horm Metab Res; 1984 Dec; 16(12):658-62. PubMed ID: 6441763
[TBL] [Abstract][Full Text] [Related]
39. Prolactin-secreting adenomas in women. VII. Dopamine regulation of prolactin secretion.
Martin MC; Weiner RI; Monroe SE; Roberts JM; Licko V; Jaffe RB
J Clin Endocrinol Metab; 1984 Sep; 59(3):485-90. PubMed ID: 6746862
[TBL] [Abstract][Full Text] [Related]
40. Relationship between maternal prolactin levels during pregnancy and lactation in women with pituitary adenoma.
Narita O; Kimura T; Suganuma N; Osawa M; Mizutani S; Masahashi T; Asai M; Tomoda Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 May; 37(5):758-62. PubMed ID: 3998551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
